ZOMDF Zomedica Corp.
Pharmaceutical Preparations · OTC · SEC CIK 1684144 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.3%
TTM net income YoY81.1%
TTM EPS YoY88.9%
Revenue 3-yr CAGR17.2%
Net income 3-yr CAGR—
Margins
Gross margin64.0%
Operating margin-45.4%
Net margin-41.4%
FCF margin-30.8%
EBITDA margin-40.0%
Returns
ROE-14.3%
ROA-13.0%
ROIC (approx.)-13.3%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets9.3%
Debt / equity0.00x
Current ratio6.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $32.03M | $27.29M |
| Cost of revenue | $10.35M | $8.20M |
| Gross profit | $21.68M | $19.09M |
| R&D expense | $7.17M | $7.27M |
| SG&A expense | $24.50M | $29.66M |
| Operating income | -$84.35M | -$51.05M |
| Pretax income | -$82.14M | -$47.54M |
| Income tax | -$278,000 | -$557,000 |
| Net income | -$81.86M | -$46.98M |
| EBITDA | -$82.30M | -$49.51M |
| EPS (basic) | -0.08 | -0.05 |
| EPS (diluted) | -0.08 | -0.05 |
| Weighted avg. shares (diluted) | 979.95M | 979.95M |
| Balance sheet | ||
| Cash & equivalents | $9.02M | $7.02M |
| Receivables | $3.01M | $2.42M |
| Inventory | $5.54M | $5.06M |
| Current assets | $64.04M | $81.77M |
| PP&E, net | $20.91M | $24.59M |
| Goodwill | $0 | $45.56M |
| Intangibles | $38.81M | $52.54M |
| Total assets | $127.04M | $207.36M |
| Current liabilities | $9.45M | $9.33M |
| Total liabilities | $11.64M | $11.70M |
| Shareholders' equity | $115.40M | $195.66M |
| Shares outstanding | 979.95M | 979.95M |
| Cash flow statement | ||
| Operating cash flow | -$17.65M | -$23.63M |
| Capital expenditure | $567,000 | $5.21M |
| Free cash flow | -$18.22M | -$28.84M |
| Investing cash flow | $19.57M | $17.85M |
| Financing cash flow | — | -$70,000 |
| Depreciation & amortization | $2.06M | $1.54M |
| Stock-based compensation | $2.47M | $2.78M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.